272 patients with pneumoconiosis participated in the 52-week study and were randomized to pirfenidone or placebo.
This study is a randomized, double-blind, placebo-controlled, multicenter clinical study.~The main purpose of this study was to confirm the efficacy and safety of pirfenidone capsules in the treatment of pneumoconiosis.